Assessment

PI 3 – Diagnostic assessment rate

PI 3 definition

The percentage of people who returned a positive NBCSP screening test (warranting further assessment) between 1 January 2024 and 31 December 2024 and had follow-up diagnostic assessment within that period or by 31 December 2025.

Rationale: The appropriate movement of people from participation to diagnostic assessment is a key indicator of the efficiency of the program and its impact in reducing morbidity and mortality from bowel cancer. While not all participants with a positive screen will necessarily have an assessment, according to the Population Based Screening Framework (Standing Committee on Screening 2018), systems should be in place to ensure timely follow-up to diagnostic assessment for individuals with a positive screening test.

Data quality: This indicator relies on information being returned to the NCSR (ACSQHC 2020); however, this reporting is not mandated by the NBCSP and is known to be incomplete. Therefore, there is an unknown level of under-reporting for this indicator, and levels of under-reporting may differ across groups (for example, across jurisdictions, and across remoteness and socioeconomic areas). Participants with only an MBS claim for colonoscopy services are included (and assumed to have been performed in a private health-care setting), though outcomes from this colonoscopy source are not known, and MBS claim data prior 2020 are incomplete. In this report, colonoscopy data have also been supplemented with Participant follow-up function (PFUF) data for those who had a positive screening test. See Improvements to the known colonoscopy count in Appendix A for further details.

Guide to interpretation: This indicator includes all people with a positive screen in the defined period, not all those invited in the defined period.
Those aged 45–49 can now request a screening kit; however, this age group is not reported in this performance indicator.

National diagnostic assessment rate, 2024: 85.4%.

The following apply to the 73,745 participants with a positive screening test in 2024:

Australia-wide: A total of 62,981 people had a follow-up diagnostic assessment (colonoscopy) recorded – an overall Australia-wide diagnostic assessment rate of 85.4% (Table A3.10).

Sex and age: Diagnostic assessment rates were higher for females (87%) than males (84%) and were slightly lower for people aged 70–74 (82%) than for younger target age groups (87%–85% for age groups 50–64 to 65–69) (Figure 3.10).

Health-care provider: Most diagnostic assessments (57%; 35,979) recorded were performed through the private health-care system, with an additional 29% (18,343 assessments) recorded through the public health-care system (Table A3.11). The remaining 14% (8,659 diagnostic assessments) did not state through which system (public or private) the follow-up assessment was performed. As this indicator relies on information being reported to the NCSR (ACSQHC 2020), and because reporting is not mandated by the NBCSP, differences in the performance of diagnostic assessments by public and private providers should be considered in light of these limitations.

Figure 3.10: Diagnostic assessment rate (colonoscopy) of people aged 50-74, by sex and age group, Australia, 2024

This vertical bar chart depicts the diagnostic assessment rate for males and females by age group. It shows that the diagnostic assessment rates were higher for females than males and were slightly lower for people aged 70–74 (83%) than for people aged 50–69 (85%–89%).

Source: Table A3.10.

Trend: Monitoring reports before 2016 used a different methodology to analyse the diagnostic assessment rate. This means that trend comparisons with rates published in those earlier reports cannot be made. To allow trends to be compared over time, the new indicator specifications have been applied retrospectively to earlier years of program data within this report. However, note that from 2021 colonoscopy form data and MBS claims have been supplemented with Participant follow-up function (PFUF) data, so direct comparisons between 2021 and earlier time periods should not be made. Since 2021, the follow-up diagnostic assessment rate has remained in the 85–86% range (Figure 3.11).

Figure 3.11: Diagnostic assessment rate (colonoscopy) of people aged 50–74, Australia, 2007–2024

This line chart depicts the diagnostic assessment rate for the period from 2007 to 2024. It shows that the diagnostic assessment rate was stable at between 77% and 78% between 2007 and 2011, and then trended down from 75% in 2012 to 62% in 2020. From 2021, Participant follow-up function (PFUF) data have been included to supplement colonoscopy form data; this has increased the diagnostic assessment rate to 85%. Due to this data prior to 2021 cannot be compared with later data.

Source: Table A3.14.

State or territory: The follow-up diagnostic assessment rate was highest for people living in Tasmania (90%) and lowest for those living in New South Wales (81%) (Figure 3.12). Note that differences in form return and varying pathway practices for diagnostic assessment may affect the results across jurisdictions.

Figure 3.12: Diagnostic assessment rate (colonoscopy) of people aged 50-74, by state and territory, Australia, 2024

This vertical bar chart depicts the diagnostic assessment rate by state or territory. It shows that the diagnostic assessment rate was highest for people living in Tasmania (90%) and lowest for people living in New South Wales (81%). Note that differences in form return and varying pathway practices for diagnostic assessment may affect the results across jurisdictions.

Source: Table A3.12.

Remoteness area: The follow-up diagnostic assessment rate was highest for people living in Inner regional areas (87%) and lowest for people living in Very remote areas (84%) (Figure 3.13a).

Socioeconomic area: The follow-up diagnostic assessment rate was highest for people living in the highest socioeconomic areas (89%) and lowest for those living in the lowest socioeconomic areas (81%) (Figure 3.13b).

Figure 3.13a: Diagnostic assessment rate (colonoscopy) of people aged 50-74, by remoteness area, Australia, 2024

This figure shows that the diagnostic assessment rate was highest for people living in Inner regional areas (87%) and lowest for people living in Very remote areas (84%).

Source: Table A3.12.

Figure 3.13b: Diagnostic assessment rate (colonoscopy) of people aged 50-74, by socioeconomic area, Australia, 2024

This figure shows that the diagnostic assessment rate was highest for people living in the highest socioeconomic areas (89%) and lowest for people living in the lowest socioeconomic areas (81%).

Source: Table A3.12.

Indigenous status: Indigenous Australians had a lower follow-up diagnostic assessment rate than non-Indigenous Australians (79% compared with 86%, respectively) (Table A3.13).

Preferred language spoken at home: People who preferred to speak a language other than English at home had a lower follow-up diagnostic assessment rate than those who spoke English at home (79% compared with 86%, respectively) (Table A3.13).

Disability status: People reporting severe or profound activity limitation had a lower follow‑up diagnostic assessment rate than those not reporting such limitation (70% compared with 87%, respectively) (Table A3.13). Note that from 2025 the simplified participant details form no longer asks for self-reported disability status. This disaggregation will be phased out in future reports in favour of future data linkage projects collecting disability status.

PI 4 – Time between positive screen and diagnostic assessment

PI 4 definition

For those who received a positive NBCSP screening test (warranting further assessment) between 1 January 2024 and 31 December 2024, the median time between the positive screen and a follow-up diagnostic assessment within that period or by 31 December 2025.

Rationale: Waiting for a definitive diagnosis after a positive screen can create anxiety. There are various steps, participant decisions, and waiting times that occur along the pathway between a positive screen and a diagnostic assessment. Therefore, this indicator should not be considered a hospital wait time indicator. However, after a positive screen, further diagnostic assessment should occur in a timely fashion as there is a defined risk of bowel cancer in those with a positive screening test – and any harms (such as anxiety) from a positive screen should be minimised.

Data quality: This indicator relies on information being reported to the NCSR (ACSQHC 2020); however, this reporting is not mandated by the NBCSP and is known to be incomplete. Therefore, there is an unknown level of under-reporting for this indicator, and levels of under-reporting may differ across groups (for example, across jurisdictions and across remoteness and socioeconomic areas). Participants with only an MBS claim for colonoscopy services are included (and assumed to have been performed in a private health-care setting), though outcomes from this colonoscopy source are not known. In this report colonoscopy data have been supplemented with Participant follow-up function (PFUF) data for those who had a positive screening test. See Improvements to the known colonoscopy count in Appendix A for further details.

Guide to interpretation: This indicator includes all people with a positive screen in the defined period, not all those invited in the defined period.

Details of the number and proportion of participants for whom time between positive screen and diagnostic assessment was less than or equal to 30, 60, 120, 180, or 360 days, or greater, are included in tables A3.15–A3.17 (Appendix A), together with median time and 90th percentile information in tables A3.18–A3.22. 

Those aged 45–49 can now request a screening kit; however, this age group is not reported in this performance indicator.

National median time between positive screen and diagnostic assessment, 2024: 62 days.

The following apply for the 73,745 participants who had a positive screening test in 2024 with a diagnostic assessment recorded:

Australia-wide: The median time between positive screen and assessment was 62 days (Table A3.18).

Sex: The median time between a positive screen and diagnostic assessment was 62 days for males and 61 days for females (Figure 3.14).

Age: The median time between a positive screen and diagnostic assessment was from 61 to 62 days across age groups (Figure 3.14).

Health-care provider: The median time between a positive screen and diagnostic assessment for people who went through the private or public health-care systems was 49 and 85 days, respectively (Table A3.19).

Around 14% of diagnostic assessments did not state through which system (public or private) the follow-up assessment was performed. As this indicator relies on information being reported to the NCSR (ACSQHC 2020), and since reporting is not mandated by the NBCSP, differences in wait times by public and private providers should be considered in light of these limitations.

Figure 3.14: Median time (in days) between positive screen and diagnostic assessment of people aged 50-74, by sex and age, Australia, 2024

This vertical bar chart shows the median time (in days) between a positive screen and a diagnostic assessment for males and females by age group. It shows that males and females had the same median time between a positive screen and assessment (62 days, respectively). The median time between a positive screen and diagnostic assessment was 61 to 63 days across age groups.

Source: Table A3.18.

Trend: Monitoring reports before 2016 did not include this analysis, so trend comparisons with data from these earlier reports cannot be made. To allow trends to be compared over time, the new indicator specifications have been applied retrospectively to earlier years of program data within this report. However, note that from 2021 colonoscopy form data and MBS claims have been supplemented with Participant follow-up function (PFUF) data, so direct comparisons between 2021 and earlier time periods should not be made. The median time between a positive screen and diagnostic assessment has been 62 days for the last three years (2022–2024) (Figure 3.15).

Figure 3.15: Median time (in days) between positive screen and diagnostic assessment of people aged 50-74, Australia, 2007-2024

This line chart shows that the median time between a positive screen and a diagnostic assessment fluctuated between 51 and 58 days from 2007 to 2018 and reached the lowest value in the history of the program with 49 days in 2020. There were no significant differences between males and females. From 2021, Participant follow-up function (PFUF) data have been included to supplement colonoscopy form data; this has increased the median days to assessment, possibly due to later assessments now being included (which raise the median days). Due to this, data prior to 2021 cannot be compared with later data.

Source: Table A3.22.

State or territory: The median time between a positive screen and diagnostic assessment was highest for people living in the Northern Territory (87 days) and lowest for those living in Victoria (50 days) (Figure 3.16). Note that differences in form return and varied pathway practices for diagnostic assessment may affect the results across jurisdictions.

Figure 3.16: Median time (in days) between positive screen and diagnostic assessment of people aged 50-74, by state or territory, Australia, 2024

This vertical bar chart shows that the median time between a positive screen and a diagnostic assessment was highest for people living in the Northern Territory (87 days) and lowest for people living in Victoria (50 days). Note that differences in form return and varying pathway practices for diagnostic assessment may affect the results across jurisdictions.

Source: Table A3.20.

Remoteness area: The median time between a positive screen and diagnostic assessment was highest for people living in Remote areas (80 days) and lowest for those in Major cities (58 days) (Figure 3.17a).

Socioeconomic area: The median time between a positive screen and diagnostic assessment was highest for people living in the lowest socioeconomic areas (71 days) and lowest for those in the highest socioeconomic areas (50 days) (Figure 3.17b).

Figure 3.17a: Median time (in days) between positive screen and diagnostic assessment of people aged 50-74, by remoteness area, Australia, 2024

The figure shows that the median time was highest for people living in Remote areas with 80 days and lowest for people living in Major cities with 58 days.

Source: Table A3.20.

Figure 3.17b: Median time (in days) between positive screen and diagnostic assessment of people aged 50-74, by socioeconomic area, Australia, 2024

The figure shows that the median time was highest for people living in the lowest socioeconomic areas with 71 days and lowest for people living in the highest socioeconomic areas with 50 days.

Source: Table A3.20.

Indigenous status: There was a longer median time between a positive screen and diagnostic assessment for Indigenous Australians (77 days) than for non-Indigenous Australians (61 days) (Table A3.21).

Preferred language spoken at home: Those who preferred to speak a language other than English at home had a longer median time between a positive screen and diagnostic assessment compared with those who spoke English at home (64 and 61 days, respectively) (Table A3.21).

Disability status: Participants reporting severe or profound activity limitation had a longer median time between a positive screen and diagnostic assessment (82 days) than those not reporting such limitation (60 days) (Table A3.21). Note that from 2025 the simplified participant details form no longer asks for self-reported disability status. This disaggregation will be phased out in future reports in favour of future data linkage projects collecting disability status.